Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate

多拉韦林/拉米夫定/富马酸替诺福韦二吡呋酯

Report date: 2025/03/19 16:22:28

Base Information

Drug NameDoravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Drug Alias NameTenofovir Disoproxil Fumarate/Lamivudine/DoravirineDoravirine/富马酸替诺福韦二吡呋酯/拉米夫定富马酸替诺福韦二吡呋酯/拉米夫定/DoravirineMK-1439/lamivudine/tenofovir disoproxil fumarateDoravirine/Tenofovir Disoproxil Fumarate/Lamivudine +[8] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitorsHBV DNA Polymerase inhibitors
TargetsReverse transcriptaseHBV DNA Polymerase
Therapy Area/IndicationsOverweightObesityHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2018/08/30
Country/TerritoryUnited StatesThailandMexico +[6] 
CombinationsYes DoravirineLamivudineTenofovir Disoproxil Fumarate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme BvInstituto Mexicano Del Seguro SocialMerck & Co Inc +[5] 
Inactive CompaniesN/A
Active IndicationsOverweightObesityHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AR
Related LinksN/A